Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
Icahn School Of Medicine at Mount Sinai, New York, NY, USA.
Background: Despite increasing knowledge of the etiology of neurodegenerative diseases, translation of these benefits into therapeutic advances for Alzheimer's Disease and related diseases (ADRD) has been slow. Drug repurposing is a promising strategy for identifying new uses for approved drugs beyond their initial indications. We developed a high-throughput drug screening platform aimed at identifying drugs capable of reducing proteotoxicity in vivo (Aß toxicity in Caenorhabditis elegans) AND inhibiting microglial inflammation (TNF-alpha IL-6), both implicated in driving AD(figure attached with sample of results in C.
View Article and Find Full Text PDFDementia Care Practice.
Alzheimers Dement
December 2024
Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Background: The United States faces a growing challenge with over 6.5 million people living with dementia (PLwD). PLwD and their caregivers struggle with cognitive, functional, behavioral, and psychosocial issues.
View Article and Find Full Text PDFDementia Care Practice.
Alzheimers Dement
December 2024
University of Pennsylvania, Philadelphia, PA, USA.
Background: Systematic approaches are essential for adapting and tailoring implementation strategies to specific dementia care settings if we are to move evidence-based practice into 'real world' care that reaches most persons living with dementia. Care of Persons with Dementia in their Environments (COPE) is an evidence-based dementia care program that provides families with skills to maximize functional abilities and quality of life of persons with dementia and reduce difficulties managing day-to-day care challenges for family caregivers. The COPE in PACE study was a national non-inferiority trial that involved the implementation of COPE in Programs of All-Inclusive Care of the Elderly (PACE)- which provide support for nursing home eligible Medicaid and Medicare enrollees (NCT04165213).
View Article and Find Full Text PDFDementia Care Practice.
Alzheimers Dement
December 2024
CMS Innovation Center at Centers for Medicare & Medicaid Services, Washington, DC, USA.
Examining Lung Cancer Screening Uptake in the United States: Recent Research and Limitations of Public-Use Data.
Cancer Epidemiol Biomarkers Prev
January 2025
Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas.
Eligibility criteria for lung cancer screening (LCS) were updated by the Centers for Medicare & Medicaid Services in 2022 following an updated recommendation from the United States Preventive Services Task Force. Recently, research has examined LCS use in the United States following this change, which centered on lowering the age to begin screening from 55 to 50 years and the smoking history threshold from 30 to 20 pack-years. These studies, including the accompanying article from Gudina and colleagues, have used the 2022 Behavioral Risk Factors Surveillance System data, which are publicly available and nationally representative.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!